Impact of integrated viral DNA on the goal to clear hepatitis B surface antigen with different therapeutic strategies
•Loss of hepatitis B surface antigen (HBsAg) from blood is a criterion for cure.•Current antiviral treatment controls replication but rarely achieves HBsAg loss.•Persistent HBsAg levels are likely due to expression from integrated viral DNA.•Therapies that also target integrated DNA are highly deman...
Saved in:
| Published in | Current opinion in virology Vol. 30; pp. 24 - 31 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.06.2018
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1879-6257 1879-6265 1879-6265 |
| DOI | 10.1016/j.coviro.2018.01.011 |
Cover
| Abstract | •Loss of hepatitis B surface antigen (HBsAg) from blood is a criterion for cure.•Current antiviral treatment controls replication but rarely achieves HBsAg loss.•Persistent HBsAg levels are likely due to expression from integrated viral DNA.•Therapies that also target integrated DNA are highly demanded.
A hallmark of hepatitis B virus (HBV) infection is the presence of hepatitis B surface antigen (HBsAg) in the serum of patients. Sustained loss of HBV DNA and HBsAg from the blood are main goals for treatment, and considered as functional cure. It is rarely achieved with long-term nucleoside analogue treatment though, both because cccDNA, the template for viral replication, is not completely cleared, and probably also because hepatocytes with HBV DNA integrated into their chromosomes persist and continue to produce large amounts of HBsAg. Therefore, loss of HBsAg requires that both cccDNA and integrated DNA are cleared or their expression blocked. Recent data indicate that this may be achieved in some patients by stopping nucleoside analogue treatment, and that HBsAg-levels can be reduced by using specific interfering RNA. In the future, targeted degradation or disruption of HBV DNA might be possible using genome editing techniques such as CRISPR/Cas9. |
|---|---|
| AbstractList | •Loss of hepatitis B surface antigen (HBsAg) from blood is a criterion for cure.•Current antiviral treatment controls replication but rarely achieves HBsAg loss.•Persistent HBsAg levels are likely due to expression from integrated viral DNA.•Therapies that also target integrated DNA are highly demanded.
A hallmark of hepatitis B virus (HBV) infection is the presence of hepatitis B surface antigen (HBsAg) in the serum of patients. Sustained loss of HBV DNA and HBsAg from the blood are main goals for treatment, and considered as functional cure. It is rarely achieved with long-term nucleoside analogue treatment though, both because cccDNA, the template for viral replication, is not completely cleared, and probably also because hepatocytes with HBV DNA integrated into their chromosomes persist and continue to produce large amounts of HBsAg. Therefore, loss of HBsAg requires that both cccDNA and integrated DNA are cleared or their expression blocked. Recent data indicate that this may be achieved in some patients by stopping nucleoside analogue treatment, and that HBsAg-levels can be reduced by using specific interfering RNA. In the future, targeted degradation or disruption of HBV DNA might be possible using genome editing techniques such as CRISPR/Cas9. A hallmark of hepatitis B virus (HBV) infection is the presence of hepatitis B surface antigen (HBsAg) in the serum of patients. Sustained loss of HBV DNA and HBsAg from the blood are main goals for treatment, and considered as functional cure. It is rarely achieved with long-term nucleoside analogue treatment though, both because cccDNA, the template for viral replication, is not completely cleared, and probably also because hepatocytes with HBV DNA integrated into their chromosomes persist and continue to produce large amounts of HBsAg. Therefore, loss of HBsAg requires that both cccDNA and integrated DNA are cleared or their expression blocked. Recent data indicate that this may be achieved in some patients by stopping nucleoside analogue treatment, and that HBsAg-levels can be reduced by using specific interfering RNA. In the future, targeted degradation or disruption of HBV DNA might be possible using genome editing techniques such as CRISPR/Cas9.A hallmark of hepatitis B virus (HBV) infection is the presence of hepatitis B surface antigen (HBsAg) in the serum of patients. Sustained loss of HBV DNA and HBsAg from the blood are main goals for treatment, and considered as functional cure. It is rarely achieved with long-term nucleoside analogue treatment though, both because cccDNA, the template for viral replication, is not completely cleared, and probably also because hepatocytes with HBV DNA integrated into their chromosomes persist and continue to produce large amounts of HBsAg. Therefore, loss of HBsAg requires that both cccDNA and integrated DNA are cleared or their expression blocked. Recent data indicate that this may be achieved in some patients by stopping nucleoside analogue treatment, and that HBsAg-levels can be reduced by using specific interfering RNA. In the future, targeted degradation or disruption of HBV DNA might be possible using genome editing techniques such as CRISPR/Cas9. A hallmark of hepatitis B virus (HBV) infection is the presence of hepatitis B surface antigen (HBsAg) in the serum of patients. Sustained loss of HBV DNA and HBsAg from the blood are main goals for treatment, and considered as functional cure. It is rarely achieved with long-term nucleoside analogue treatment though, both because cccDNA, the template for viral replication, is not completely cleared, and probably also because hepatocytes with HBV DNA integrated into their chromosomes persist and continue to produce large amounts of HBsAg. Therefore, loss of HBsAg requires that both cccDNA and integrated DNA are cleared or their expression blocked. Recent data indicate that this may be achieved in some patients by stopping nucleoside analogue treatment, and that HBsAg-levels can be reduced by using specific interfering RNA. In the future, targeted degradation or disruption of HBV DNA might be possible using genome editing techniques such as CRISPR/Cas9. |
| Author | Larsson, Simon B Rydell, Gustaf E Lindh, Magnus |
| Author_xml | – sequence: 1 givenname: Magnus orcidid: 0000-0002-8729-7462 surname: Lindh fullname: Lindh, Magnus email: magnus.lindh@microbio.gu.se – sequence: 2 givenname: Gustaf E orcidid: 0000-0001-8093-2251 surname: Rydell fullname: Rydell, Gustaf E – sequence: 3 givenname: Simon B orcidid: 0000-0002-0964-6137 surname: Larsson fullname: Larsson, Simon B |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29453099$$D View this record in MEDLINE/PubMed https://gup.ub.gu.se/publication/269040$$DView record from Swedish Publication Index |
| BookMark | eNqFkUtv1DAUhS3UipbSf4CQl2xmsBM_EhZIpTxaqSobWFuOc53xKGMH22nFv8dRyixYUOvKL33nLM55hU588IDQG0q2lFDxfr814cHFsK0IbbaElqEv0DltZLsRleAnxzuXZ-gypT0piwvacvoSnVUt4zVp23M03x4mbTIOFjufYYg6Q4-LtR7x5_srHDzOO8BDKO8csBlBR7yDSWeXXcKfcJqj1Qaw9tkN4PGjyzvcO2shgs-LOOoJ5uwMTnlxHxyk1-jU6jHB5dN5gX5-_fLj-mZz9_3b7fXV3cYwQnLZOe8q2diGt1VvpZCdNU0jJAMiK6GlIMAI6zm1vOttI-q6p5aJtrasaSmrL9Bm9U2PMM2dmqI76PhbBe3UME-qfA2zSqAq0RJGCv9u5acYfs2Qsjq4ZGActYcwJ1URUhNOJV3Qt0_o3B2gP1r_jbYAbAVMDClFsEeEErWUqPZqLVEtJSpCy9Ai-_CPzLhc0g6-pOfG58QfVzGUUB8cRJWMA2-gdxFMVn1w_zf4A0rBuqQ |
| CitedBy_id | crossref_primary_10_1172_JCI121957 crossref_primary_10_1021_acsinfecdis_0c00638 crossref_primary_10_1021_acsinfecdis_8b00156 crossref_primary_10_1093_infdis_jiab469 crossref_primary_10_1186_s40364_024_00611_y crossref_primary_10_1002_hep4_1507 crossref_primary_10_3390_microorganisms13010157 crossref_primary_10_1155_2022_4133283 crossref_primary_10_3390_cells10061294 crossref_primary_10_1002_rmv_2051 crossref_primary_10_3390_v13050745 crossref_primary_10_1002_hep4_1764 crossref_primary_10_1016_j_ebiom_2019_10_022 crossref_primary_10_1093_infdis_jiaa572 crossref_primary_10_1093_infdis_jiae045 crossref_primary_10_1097_COH_0000000000000616 crossref_primary_10_1111_jvh_13356 crossref_primary_10_3390_microorganisms10020253 crossref_primary_10_3390_v14030557 crossref_primary_10_3389_fmicb_2018_00662 crossref_primary_10_1007_s00535_020_01700_z crossref_primary_10_1016_j_jhep_2021_04_051 |
| Cites_doi | 10.1016/j.jhep.2012.11.039 10.1016/j.jhep.2014.11.031 10.1002/hep.27381 10.1172/JCI92812 10.3390/v9040075 10.1016/j.jhep.2016.02.021 10.1136/gutjnl-2013-305517 10.1053/j.gastro.2008.07.008 10.3389/fcimb.2017.00091 10.1136/gutjnl-2014-308989 10.1038/ncomms12992 10.1128/JVI.00430-14 10.1128/JVI.70.7.4567-4575.1996 10.1002/cncr.29537 10.1016/j.jhep.2015.01.002 10.1016/j.jhep.2016.08.009 10.1128/JCM.00760-17 10.1111/jvh.12387 10.1111/jgh.13422 10.1016/j.jhep.2017.07.012 10.1016/j.jviromet.2007.01.027 10.1111/liv.13253 10.1111/jvh.12380 10.1136/gutjnl-2015-309809 10.1016/j.jhep.2017.03.021 10.1093/infdis/jiw412 10.1128/JVI.00833-10 10.1126/scitranslmed.aan0241 10.1053/j.gastro.2010.04.048 10.1038/ncomms3513 10.1111/liv.12345 10.1002/hep.21282 10.1016/j.virol.2017.05.017 10.1172/JCI83339 10.1093/infdis/jiv397 10.1111/jvh.12688 10.1002/hep.28438 10.1038/ng.2295 10.1016/j.jhep.2016.01.026 10.1038/nature17170 10.1053/j.gastro.2016.07.012 10.1016/0016-5085(87)90858-4 10.1016/j.cmi.2015.02.010 10.1016/j.jhep.2013.08.023 10.1001/jama.295.1.65 10.1245/s10434-014-4043-5 10.1053/j.gastro.2012.05.039 10.1186/s12985-015-0447-5 10.1038/srep13734 10.1002/jmv.24841 |
| ContentType | Journal Article |
| Copyright | 2018 Elsevier B.V. Copyright © 2018 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2018 Elsevier B.V. – notice: Copyright © 2018 Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS F1U |
| DOI | 10.1016/j.coviro.2018.01.011 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic SwePub SwePub Articles SWEPUB Göteborgs universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1879-6265 |
| EndPage | 31 |
| ExternalDocumentID | oai_gup_ub_gu_se_269040 29453099 10_1016_j_coviro_2018_01_011 S1879625717301554 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .~1 0R~ 1~. 4.4 457 53G 8P~ 9JM AAAJQ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AARKO AAXUO ABBQC ABJNI ABLVK ABMAC ABMZM ABRWV ABXDB ABYKQ ACDAQ ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AESVU AEXOQ AFKWA AFTJW AFXIZ AGEKW AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV CJTIS EBS EFJIC EFLBG EJD FDB FIRID FNPLU FYGXN GBLVA HZ~ J1W KOM LCYCR LUGTX M41 MO0 N9A O-L O9- OAUVE P-8 P-9 PC. Q38 QYZTP RIG ROL SDF SES SNL SPCBC SSH SSI SSZ T5K ~G- AAQFI AATTM AAXKI AAYWO AAYXX ABWVN ACIEU ACMHX ACRPL ACVFH ADCNI ADNMO ADSLC AEIPS AEUPX AFJKZ AFPUW AGCQF AGRNS AGWPP AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION CGR CUY CVF ECM EIF NPM 7X8 ACLOT EFKBS ~HD ADTPV AOWAS F1U |
| ID | FETCH-LOGICAL-c400t-c455b278f8592df767bfc88674e0726a760e404d51f5bdf8633d1f4693f489143 |
| IEDL.DBID | AIKHN |
| ISSN | 1879-6257 1879-6265 |
| IngestDate | Tue Sep 09 23:34:17 EDT 2025 Sat Sep 27 22:28:36 EDT 2025 Thu Apr 03 07:05:14 EDT 2025 Thu Apr 24 23:12:06 EDT 2025 Tue Jul 01 01:35:01 EDT 2025 Fri Feb 23 02:25:46 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | Copyright © 2018 Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c400t-c455b278f8592df767bfc88674e0726a760e404d51f5bdf8633d1f4693f489143 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-8729-7462 0000-0001-8093-2251 0000-0002-0964-6137 |
| PMID | 29453099 |
| PQID | 2003051710 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | swepub_primary_oai_gup_ub_gu_se_269040 proquest_miscellaneous_2003051710 pubmed_primary_29453099 crossref_primary_10_1016_j_coviro_2018_01_011 crossref_citationtrail_10_1016_j_coviro_2018_01_011 elsevier_sciencedirect_doi_10_1016_j_coviro_2018_01_011 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-06-01 |
| PublicationDateYYYYMMDD | 2018-06-01 |
| PublicationDate_xml | – month: 06 year: 2018 text: 2018-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Current opinion in virology |
| PublicationTitleAlternate | Curr Opin Virol |
| PublicationYear | 2018 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Freitas, Cunha, Menne, Gudima (bib0390) 2014; 88 Kim, Lim, An, Lee, Shim, Kim, Lee, Chung, Lee, Suh (bib0350) 2014; 63 Berg, Simon, Mauss, Schott, Heyne, Klass, Eisenbach, Welzel, Zachoval, Felten (bib0500) 2017; 67 Larsson, Eilard, Malmström, Hannoun, Dhillon, Norkrans, Lindh (bib0370) 2014; 34 Maasoumy, Wiegand, Jaroszewicz, Bremer, Lehmann, Deterding, Taranta, Manns, Wedemeyer, Glebe (bib0465) 2015; 21 van Bömmel, Bartens, Mysickova, Hofmann, Krüger, Berg, Edelmann (bib0475) 2015; 61 Kim, Loomba, Berg, Aguilar Schall, Yee, Dinh, Flaherty, Martins, Therneau, Jacobson (bib0355) 2015; 121 Decorsière, Mueller, van Breugel, Abdul, Gerossier, Beran, Livingston, Niu, Fletcher, Hantz (bib0295) 2016; 531 Gao, Li, Meng, Zhang, Zhao, Shang, Li, Su, Li, Liu (bib0345) 2017; 55 Lin, Yang, Kuo, Liu, Yang, Sung, Lin, Wang, Wang, Shen (bib0480) 2014; 3 Rivino, Le Bert, Gill, Kunasegaran, Cheng, Tan, Becht, Hansi, Foster, Su (bib0520) 2018 Bertoletti, Ferrari (bib0425) 2016; 64 Papatheodoridis, Chan, Hansen, Janssen, Pietro Lampertico (bib0320) 2015; 62 Sung, Zheng, Li, Chen, Liu, Li, Lee, Lee, Ariyaratne, Tennakoon (bib0405) 2012; 44 Larsson, Malmström, Hannoun, Norkrans, Lindh (bib0375) 2015 Yuen, Wong, Fung, Ip, But, Hung, Lau, Yuen, Lai (bib0360) 2008; 135 Li, Sheng, Wang, Yang, Liang, Huang, Liu, Li, Yang, Yang (bib0490) 2017; 7 Levrero, Zucman-Rossi (bib0300) 2016; 64 Papatheodoridis, Goulis, Manolakopoulos, Margariti, Exarchos, Kokkonis, Hadziyiannis, Papaioannou, Manesis, Pectasides (bib0285) 2014; 60 Liu, Yang, Lee, Lu, Jen, Wang, You, Iloeje, Chen, REVEAL-HBV Study Group (bib0275) 2010; 139 Tripodi, Larsson, Norkrans, Lindh (bib0380) 2017; 89 Su, Hu, Chen, Huang, Chuang, Lin, Wang, Su, Chen, Peng (bib0315) 2016; 36 Nassal (bib0265) 2015; 64 Yang, Mason, Summers (bib0395) 1996; 70 Tu, Mason, Clouston, Shackel, McCaughan, Yeh, Schiff, Ruszkiewicz, Chen, Harley (bib0415) 2015; 22 Rydell, Prakash, Norder, Lindh (bib0430) 2017; 509 Kim, Lee, Kim, Ha, Park, An, Lee, Shim, Kim, Lim (bib0365) 2015; 62 Hadziyannis, Sevastianos, Rapti, Vassilopoulos, Hadziyannis (bib0495) 2012; 143 Wooddell, Yuen, Chan, Gish, Locarnini, Chavez, Ferrari, Given, Hamilton, Kanner (bib0290) 2017; 9 Chevaliez, Hézode, Bahrami, Grare, Pawlotsky (bib0280) 2013; 58 Chen, Yang, Su, Jen, You, Lu, Huang, Iloeje, REVEAL-HBV Study Group (bib0310) 2006; 295 Zhao, Yang, Lin, Ma, Guo, Yang, Zhang, Han, Wei, Pan (bib0400) 2016; 65 Mason, Liu, Aldrich, Litwin, Yeh (bib0410) 2010; 84 Tang, Alaei-Mahabadi, Samuelsson, Lindh, Larsson (bib0440) 2013; 4 Chien, Liu, Lee, Jen, Batrla-Utermann, Lu, Wang, You, Yang, Chen (bib0445) 2016; 31 Zhang, Lu, Zheng, Wang, Bai, Chen, Feng, Zhang, Yuan (bib0330) 2016; 126 Zhao, Liu, Yan, Li, Zeng, Yang, Zhao, Liu, Zhuang, Lin (bib0305) 2016; 7 Tu, Budzinska, Shackel, Urban (bib0435) 2017; 9 Jansen, Kootstra, van Dort, Takkenberg, Reesink, Zaaijer (bib0470) 2015; 213 Yao, Hung, Hu, Lu, Wang, Lee, Chen (bib0510) 2017; 7 Wursthorn, Lutgehetmann, Dandri, Volz, Buggisch, Zollner, Longerich, Schirmacher, Metzler, Zankel (bib0340) 2006; 44 van der Laan, Taimr, Kok, Sprengers, Zondervan, Tilanus, Janssen (bib0455) 2007; 142 Cornberg, Wong, Locarnini, Brunetto, Janssen, Chan (bib0335) 2017; 66 Höner Zu Siederdissen, Rinker, Maasoumy, Wiegand, Filmann, Falk, Deterding, Port, Mix, Manns (bib0515) 2016; 214 Liu, Tian, Jin, Yang, Ding, Shen, Peng, Zhou, Qiu, Dai (bib0450) 2015; 22 Désiré, Ngo, Franetich, Dembele, Mazier, Vaillant, Poynard, Thibault (bib0420) 2015; 22 Omata, Yokosuka, Imazeki, Ito, Mori, Uchiumi, Okuda (bib0385) 1987; 92 Mason, Gill, Litwin, Zhou, Peri, Pop, Hong, Naik, Quaglia, Bertoletti (bib0325) 2016; 151 Cheung, Seto, Wong, Lai, Yuen (bib0460) 2017; 24 Pietro Lampertico, Agarwal, Berg, Buti, Janssen, Papatheodoridis, Zoulim, Tacke (bib0270) 2017; 67 Papatheodoridis, Vlachogiannakos, Cholongitas, Wursthorn, Thomadakis, Touloumi, Petersen (bib0505) 2016; 63 Karimova, Beschorner, Dammermann, Chemnitz, Indenbirken, Bockmann, Grundhoff, Lüth, Buchholz, Wiesch zur (bib0485) 2015 Berg (10.1016/j.coviro.2018.01.011_sbref0500) 2017; 67 Su (10.1016/j.coviro.2018.01.011_bib0315) 2016; 36 Papatheodoridis (10.1016/j.coviro.2018.01.011_bib0320) 2015; 62 Tang (10.1016/j.coviro.2018.01.011_bib0440) 2013; 4 Bertoletti (10.1016/j.coviro.2018.01.011_bib0425) 2016; 64 van der Laan (10.1016/j.coviro.2018.01.011_bib0455) 2007; 142 Li (10.1016/j.coviro.2018.01.011_bib0490) 2017; 7 Kim (10.1016/j.coviro.2018.01.011_bib0365) 2015; 62 Tu (10.1016/j.coviro.2018.01.011_bib0415) 2015; 22 Désiré (10.1016/j.coviro.2018.01.011_bib0420) 2015; 22 van Bömmel (10.1016/j.coviro.2018.01.011_bib0475) 2015; 61 Levrero (10.1016/j.coviro.2018.01.011_bib0300) 2016; 64 Papatheodoridis (10.1016/j.coviro.2018.01.011_bib0285) 2014; 60 Tripodi (10.1016/j.coviro.2018.01.011_bib0380) 2017; 89 Tu (10.1016/j.coviro.2018.01.011_bib0435) 2017; 9 Chien (10.1016/j.coviro.2018.01.011_bib0445) 2016; 31 Mason (10.1016/j.coviro.2018.01.011_sbref0410) 2010; 84 Papatheodoridis (10.1016/j.coviro.2018.01.011_bib0505) 2016; 63 Hadziyannis (10.1016/j.coviro.2018.01.011_bib0495) 2012; 143 Cheung (10.1016/j.coviro.2018.01.011_bib0460) 2017; 24 Zhang (10.1016/j.coviro.2018.01.011_sbref0330) 2016; 126 Freitas (10.1016/j.coviro.2018.01.011_bib0390) 2014; 88 Chevaliez (10.1016/j.coviro.2018.01.011_bib0280) 2013; 58 Larsson (10.1016/j.coviro.2018.01.011_bib0370) 2014; 34 Zhao (10.1016/j.coviro.2018.01.011_bib0305) 2016; 7 Yang (10.1016/j.coviro.2018.01.011_bib0395) 1996; 70 Kim (10.1016/j.coviro.2018.01.011_bib0350) 2014; 63 Pietro Lampertico (10.1016/j.coviro.2018.01.011_bib0270) 2017; 67 Rivino (10.1016/j.coviro.2018.01.011_bib0520) 2018 Mason (10.1016/j.coviro.2018.01.011_sbref0325) 2016; 151 Decorsière (10.1016/j.coviro.2018.01.011_bib0295) 2016; 531 Yao (10.1016/j.coviro.2018.01.011_bib0510) 2017; 7 Höner Zu Siederdissen (10.1016/j.coviro.2018.01.011_bib0515) 2016; 214 Wooddell (10.1016/j.coviro.2018.01.011_sbref0290) 2017; 9 Wursthorn (10.1016/j.coviro.2018.01.011_bib0340) 2006; 44 Gao (10.1016/j.coviro.2018.01.011_bib0345) 2017; 55 Chen (10.1016/j.coviro.2018.01.011_bib0310) 2006; 295 Lin (10.1016/j.coviro.2018.01.011_bib0480) 2014; 3 Omata (10.1016/j.coviro.2018.01.011_bib0385) 1987; 92 Maasoumy (10.1016/j.coviro.2018.01.011_bib0465) 2015; 21 Nassal (10.1016/j.coviro.2018.01.011_bib0265) 2015; 64 Cornberg (10.1016/j.coviro.2018.01.011_bib0335) 2017; 66 Rydell (10.1016/j.coviro.2018.01.011_bib0430) 2017; 509 Larsson (10.1016/j.coviro.2018.01.011_bib0375) 2015 Liu (10.1016/j.coviro.2018.01.011_bib0275) 2010; 139 Yuen (10.1016/j.coviro.2018.01.011_bib0360) 2008; 135 Kim (10.1016/j.coviro.2018.01.011_bib0355) 2015; 121 Karimova (10.1016/j.coviro.2018.01.011_bib0485) 2015 Zhao (10.1016/j.coviro.2018.01.011_bib0400) 2016; 65 Liu (10.1016/j.coviro.2018.01.011_bib0450) 2015; 22 Sung (10.1016/j.coviro.2018.01.011_bib0405) 2012; 44 Jansen (10.1016/j.coviro.2018.01.011_bib0470) 2015; 213 |
| References_xml | – year: 2015 ident: bib0375 article-title: Mechanisms downstream of reverse transcription reduce serum levels of HBV DNA but not of HBsAg in chronic hepatitis B virus infection publication-title: Virology J – volume: 7 start-page: 12992 year: 2016 end-page: 13010 ident: bib0305 article-title: Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma publication-title: Nat Commun – volume: 22 start-page: 718 year: 2015 end-page: 726 ident: bib0420 article-title: Definition of an HBsAg to DNA international unit conversion factor by enrichment of circulating hepatitis B virus forms publication-title: J Viral Hepat – volume: 64 start-page: S84 year: 2016 end-page: S101 ident: bib0300 article-title: Mechanisms of HBV-induced hepatocellular carcinoma publication-title: J Hepatol – volume: 21 year: 2015 ident: bib0465 article-title: Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D publication-title: Clin Microbiol Infect – volume: 295 start-page: 65 year: 2006 end-page: 73 ident: bib0310 article-title: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level publication-title: JAMA – volume: 89 start-page: 1937 year: 2017 end-page: 1943 ident: bib0380 article-title: Smaller reduction of hepatitis B virus DNA in liver tissue than in serum in patients losing HBeAg publication-title: J Med Virol – volume: 4 start-page: 2513 year: 2013 ident: bib0440 article-title: The landscape of viral expression and host gene fusion and adaptation in human cancer publication-title: Nat Commun – volume: 92 start-page: 192 year: 1987 end-page: 196 ident: bib0385 article-title: Correlation of hepatitis B virus DNA and antigens in the liver. A study in chronic liver disease publication-title: Gastroenterology – volume: 58 start-page: 676 year: 2013 end-page: 683 ident: bib0280 article-title: Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely publication-title: J Hepatol – volume: 44 start-page: 675 year: 2006 end-page: 684 ident: bib0340 article-title: Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B publication-title: Hepatology – volume: 135 start-page: 1192 year: 2008 end-page: 1199 ident: bib0360 article-title: HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma publication-title: Gastroenterology – volume: 34 start-page: e238 year: 2014 end-page: e245 ident: bib0370 article-title: HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers publication-title: Liver Int – volume: 9 year: 2017 ident: bib0435 article-title: HBV DNA integration: molecular mechanisms and clinical implications publication-title: Viruses – volume: 142 start-page: 189 year: 2007 end-page: 197 ident: bib0455 article-title: Flowcytometric quantitation of hepatitis B viral antigens in hepatocytes from regular and fine-needle biopsies publication-title: J Virol Meth – volume: 151 year: 2016 ident: bib0325 article-title: HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant publication-title: Gastroenterology – volume: 60 start-page: 62 year: 2014 end-page: 68 ident: bib0285 article-title: Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy publication-title: J Hepatol – volume: 64 start-page: S71 year: 2016 end-page: S83 ident: bib0425 article-title: Adaptive immunity in HBV infection publication-title: J Hepatol – volume: 143 year: 2012 ident: bib0495 article-title: Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir publication-title: Gastroenterlogy – volume: 65 start-page: 502 year: 2016 end-page: 511 ident: bib0400 article-title: Serum viral duplex-linear DNA proportion increases with the progression of liver disease in patients infected with HBV publication-title: Gut – volume: 3 start-page: e186 year: 2014 ident: bib0480 article-title: The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo publication-title: Mol Therapy – volume: 63 start-page: 1325 year: 2014 end-page: 1332 ident: bib0350 article-title: HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability publication-title: Gut – volume: 84 start-page: 8308 year: 2010 end-page: 8315 ident: bib0410 article-title: Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection publication-title: J Virol – volume: 22 start-page: 843 year: 2015 end-page: 850 ident: bib0450 article-title: High levels of hepatitis B surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis B viral loads publication-title: Ann Surg Oncol – volume: 70 start-page: 4567 year: 1996 end-page: 4575 ident: bib0395 article-title: Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis virus-infected liver publication-title: J Virol – year: 2018 ident: bib0520 article-title: Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation publication-title: J Clin Invest – volume: 7 start-page: 11641 year: 2017 end-page: 11649 ident: bib0490 article-title: Removal of integrated hepatitis B virus DNA using CRISPR-Cas9 publication-title: Front Cell Infect Microbiol – volume: 63 start-page: 1481 year: 2016 end-page: 1492 ident: bib0505 article-title: Discontinuation of oral antivirals in chronic hepatitis B: a systematic review publication-title: Hepatology – volume: 214 start-page: 1492 year: 2016 end-page: 1497 ident: bib0515 article-title: Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B publication-title: J Infect Dis – volume: 64 start-page: 1972 year: 2015 end-page: 1984 ident: bib0265 article-title: HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B publication-title: Gut – volume: 126 start-page: 1079 year: 2016 end-page: 1092 ident: bib0330 article-title: In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection publication-title: J Clin Invest – volume: 22 start-page: 737 year: 2015 end-page: 753 ident: bib0415 article-title: Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection publication-title: J Viral Hepat – volume: 31 start-page: 1971 year: 2016 end-page: 1977 ident: bib0445 article-title: Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis publication-title: J Gastroenterol Hepatol – volume: 67 start-page: 918 year: 2017 end-page: 924 ident: bib0500 article-title: Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients publication-title: J Hepatol – volume: 24 start-page: 654 year: 2017 end-page: 661 ident: bib0460 article-title: Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy publication-title: J Viral Hepat – volume: 213 start-page: 224 year: 2015 end-page: 232 ident: bib0470 article-title: Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon Alfa-2a and nucleos(t)ide analogues publication-title: J Infect Dis – year: 2015 ident: bib0485 article-title: CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X publication-title: Scientific Rep – volume: 36 start-page: 1755 year: 2016 end-page: 1764 ident: bib0315 article-title: Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients publication-title: Liver Int – volume: 67 start-page: 370 year: 2017 end-page: 398 ident: bib0270 article-title: EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection publication-title: J Hepatol – volume: 509 start-page: 67 year: 2017 end-page: 70 ident: bib0430 article-title: Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro publication-title: Virology – volume: 62 start-page: 956 year: 2015 end-page: 967 ident: bib0320 article-title: Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy publication-title: J Hepatol – volume: 62 start-page: 1092 year: 2015 end-page: 1099 ident: bib0365 article-title: Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance publication-title: J Hepatol – volume: 66 start-page: 398 year: 2017 end-page: 411 ident: bib0335 article-title: The role of quantitative hepatitis B surface antigen revisited publication-title: J Hepatol – volume: 55 start-page: 2972 year: 2017 end-page: 2982 ident: bib0345 article-title: Serum hepatitis B virus DNA, RNA, and HBsAg: which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment? publication-title: J Clin Microbiol – volume: 44 start-page: 765 year: 2012 end-page: 769 ident: bib0405 article-title: Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma publication-title: Nat Genetics – volume: 9 start-page: eaan0241 year: 2017 ident: bib0290 article-title: RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg publication-title: Sci Transl Med – volume: 139 start-page: 474 year: 2010 end-page: 482 ident: bib0275 article-title: Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study publication-title: Gastroenterology – volume: 88 start-page: 5742 year: 2014 end-page: 5754 ident: bib0390 article-title: Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles publication-title: J Virol – volume: 121 start-page: 3631 year: 2015 end-page: 3638 ident: bib0355 article-title: Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B publication-title: Cancer – volume: 61 start-page: 66 year: 2015 end-page: 76 ident: bib0475 article-title: Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors publication-title: Hepatology – volume: 531 year: 2016 ident: bib0295 article-title: Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor publication-title: Nature – volume: 7 year: 2017 ident: bib0510 article-title: Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg publication-title: Scientific Rep – volume: 58 start-page: 676 year: 2013 ident: 10.1016/j.coviro.2018.01.011_bib0280 article-title: Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely publication-title: J Hepatol doi: 10.1016/j.jhep.2012.11.039 – volume: 62 start-page: 1092 year: 2015 ident: 10.1016/j.coviro.2018.01.011_bib0365 article-title: Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance publication-title: J Hepatol doi: 10.1016/j.jhep.2014.11.031 – volume: 61 start-page: 66 year: 2015 ident: 10.1016/j.coviro.2018.01.011_bib0475 article-title: Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors publication-title: Hepatology doi: 10.1002/hep.27381 – volume: 3 start-page: e186 year: 2014 ident: 10.1016/j.coviro.2018.01.011_bib0480 article-title: The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo publication-title: Mol Therapy – year: 2018 ident: 10.1016/j.coviro.2018.01.011_bib0520 article-title: Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation publication-title: J Clin Invest doi: 10.1172/JCI92812 – volume: 9 year: 2017 ident: 10.1016/j.coviro.2018.01.011_bib0435 article-title: HBV DNA integration: molecular mechanisms and clinical implications publication-title: Viruses doi: 10.3390/v9040075 – volume: 64 start-page: S84 year: 2016 ident: 10.1016/j.coviro.2018.01.011_bib0300 article-title: Mechanisms of HBV-induced hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2016.02.021 – volume: 63 start-page: 1325 year: 2014 ident: 10.1016/j.coviro.2018.01.011_bib0350 article-title: HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability publication-title: Gut doi: 10.1136/gutjnl-2013-305517 – volume: 135 start-page: 1192 year: 2008 ident: 10.1016/j.coviro.2018.01.011_bib0360 article-title: HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma publication-title: Gastroenterology doi: 10.1053/j.gastro.2008.07.008 – volume: 7 year: 2017 ident: 10.1016/j.coviro.2018.01.011_bib0510 article-title: Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg≤200IU/mL publication-title: Scientific Rep – volume: 7 start-page: 11641 year: 2017 ident: 10.1016/j.coviro.2018.01.011_bib0490 article-title: Removal of integrated hepatitis B virus DNA using CRISPR-Cas9 publication-title: Front Cell Infect Microbiol doi: 10.3389/fcimb.2017.00091 – volume: 65 start-page: 502 year: 2016 ident: 10.1016/j.coviro.2018.01.011_bib0400 article-title: Serum viral duplex-linear DNA proportion increases with the progression of liver disease in patients infected with HBV publication-title: Gut doi: 10.1136/gutjnl-2014-308989 – volume: 7 start-page: 12992 year: 2016 ident: 10.1016/j.coviro.2018.01.011_bib0305 article-title: Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma publication-title: Nat Commun doi: 10.1038/ncomms12992 – volume: 88 start-page: 5742 year: 2014 ident: 10.1016/j.coviro.2018.01.011_bib0390 article-title: Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles publication-title: J Virol doi: 10.1128/JVI.00430-14 – volume: 70 start-page: 4567 year: 1996 ident: 10.1016/j.coviro.2018.01.011_bib0395 article-title: Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis virus-infected liver publication-title: J Virol doi: 10.1128/JVI.70.7.4567-4575.1996 – volume: 121 start-page: 3631 year: 2015 ident: 10.1016/j.coviro.2018.01.011_bib0355 article-title: Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B publication-title: Cancer doi: 10.1002/cncr.29537 – volume: 62 start-page: 956 year: 2015 ident: 10.1016/j.coviro.2018.01.011_bib0320 article-title: Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy publication-title: J Hepatol doi: 10.1016/j.jhep.2015.01.002 – volume: 66 start-page: 398 year: 2017 ident: 10.1016/j.coviro.2018.01.011_bib0335 article-title: The role of quantitative hepatitis B surface antigen revisited publication-title: J Hepatol doi: 10.1016/j.jhep.2016.08.009 – volume: 55 start-page: 2972 year: 2017 ident: 10.1016/j.coviro.2018.01.011_bib0345 article-title: Serum hepatitis B virus DNA, RNA, and HBsAg: which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment? publication-title: J Clin Microbiol doi: 10.1128/JCM.00760-17 – volume: 22 start-page: 718 year: 2015 ident: 10.1016/j.coviro.2018.01.011_bib0420 article-title: Definition of an HBsAg to DNA international unit conversion factor by enrichment of circulating hepatitis B virus forms publication-title: J Viral Hepat doi: 10.1111/jvh.12387 – volume: 31 start-page: 1971 year: 2016 ident: 10.1016/j.coviro.2018.01.011_bib0445 article-title: Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.13422 – volume: 67 start-page: 918 year: 2017 ident: 10.1016/j.coviro.2018.01.011_sbref0500 article-title: Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients—FINITE study publication-title: J Hepatol doi: 10.1016/j.jhep.2017.07.012 – volume: 142 start-page: 189 year: 2007 ident: 10.1016/j.coviro.2018.01.011_bib0455 article-title: Flowcytometric quantitation of hepatitis B viral antigens in hepatocytes from regular and fine-needle biopsies publication-title: J Virol Meth doi: 10.1016/j.jviromet.2007.01.027 – volume: 36 start-page: 1755 year: 2016 ident: 10.1016/j.coviro.2018.01.011_bib0315 article-title: Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients publication-title: Liver Int doi: 10.1111/liv.13253 – volume: 22 start-page: 737 year: 2015 ident: 10.1016/j.coviro.2018.01.011_bib0415 article-title: Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection publication-title: J Viral Hepat doi: 10.1111/jvh.12380 – volume: 64 start-page: 1972 year: 2015 ident: 10.1016/j.coviro.2018.01.011_bib0265 article-title: HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B publication-title: Gut doi: 10.1136/gutjnl-2015-309809 – volume: 67 start-page: 370 year: 2017 ident: 10.1016/j.coviro.2018.01.011_bib0270 article-title: EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection publication-title: J Hepatol doi: 10.1016/j.jhep.2017.03.021 – volume: 214 start-page: 1492 year: 2016 ident: 10.1016/j.coviro.2018.01.011_bib0515 article-title: Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B publication-title: J Infect Dis doi: 10.1093/infdis/jiw412 – volume: 84 start-page: 8308 year: 2010 ident: 10.1016/j.coviro.2018.01.011_sbref0410 article-title: Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection publication-title: J Virol doi: 10.1128/JVI.00833-10 – volume: 9 start-page: eaan0241 year: 2017 ident: 10.1016/j.coviro.2018.01.011_sbref0290 article-title: RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aan0241 – volume: 139 start-page: 474 year: 2010 ident: 10.1016/j.coviro.2018.01.011_bib0275 article-title: Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study publication-title: Gastroenterology doi: 10.1053/j.gastro.2010.04.048 – volume: 4 start-page: 2513 year: 2013 ident: 10.1016/j.coviro.2018.01.011_bib0440 article-title: The landscape of viral expression and host gene fusion and adaptation in human cancer publication-title: Nat Commun doi: 10.1038/ncomms3513 – volume: 34 start-page: e238 year: 2014 ident: 10.1016/j.coviro.2018.01.011_bib0370 article-title: HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers publication-title: Liver Int doi: 10.1111/liv.12345 – volume: 44 start-page: 675 year: 2006 ident: 10.1016/j.coviro.2018.01.011_bib0340 article-title: Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B publication-title: Hepatology doi: 10.1002/hep.21282 – volume: 509 start-page: 67 year: 2017 ident: 10.1016/j.coviro.2018.01.011_bib0430 article-title: Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro publication-title: Virology doi: 10.1016/j.virol.2017.05.017 – volume: 126 start-page: 1079 year: 2016 ident: 10.1016/j.coviro.2018.01.011_sbref0330 article-title: In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection publication-title: J Clin Invest doi: 10.1172/JCI83339 – volume: 213 start-page: 224 year: 2015 ident: 10.1016/j.coviro.2018.01.011_bib0470 article-title: Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon Alfa-2a and nucleos(t)ide analogues publication-title: J Infect Dis doi: 10.1093/infdis/jiv397 – volume: 24 start-page: 654 year: 2017 ident: 10.1016/j.coviro.2018.01.011_bib0460 article-title: Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy publication-title: J Viral Hepat doi: 10.1111/jvh.12688 – volume: 63 start-page: 1481 year: 2016 ident: 10.1016/j.coviro.2018.01.011_bib0505 article-title: Discontinuation of oral antivirals in chronic hepatitis B: a systematic review publication-title: Hepatology doi: 10.1002/hep.28438 – volume: 44 start-page: 765 year: 2012 ident: 10.1016/j.coviro.2018.01.011_bib0405 article-title: Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma publication-title: Nat Genetics doi: 10.1038/ng.2295 – volume: 64 start-page: S71 year: 2016 ident: 10.1016/j.coviro.2018.01.011_bib0425 article-title: Adaptive immunity in HBV infection publication-title: J Hepatol doi: 10.1016/j.jhep.2016.01.026 – volume: 531 year: 2016 ident: 10.1016/j.coviro.2018.01.011_bib0295 article-title: Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor publication-title: Nature doi: 10.1038/nature17170 – volume: 151 year: 2016 ident: 10.1016/j.coviro.2018.01.011_sbref0325 article-title: HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.07.012 – volume: 92 start-page: 192 year: 1987 ident: 10.1016/j.coviro.2018.01.011_bib0385 article-title: Correlation of hepatitis B virus DNA and antigens in the liver. A study in chronic liver disease publication-title: Gastroenterology doi: 10.1016/0016-5085(87)90858-4 – volume: 21 year: 2015 ident: 10.1016/j.coviro.2018.01.011_bib0465 article-title: Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2015.02.010 – volume: 60 start-page: 62 year: 2014 ident: 10.1016/j.coviro.2018.01.011_bib0285 article-title: Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy publication-title: J Hepatol doi: 10.1016/j.jhep.2013.08.023 – volume: 295 start-page: 65 year: 2006 ident: 10.1016/j.coviro.2018.01.011_bib0310 article-title: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level publication-title: JAMA doi: 10.1001/jama.295.1.65 – volume: 22 start-page: 843 year: 2015 ident: 10.1016/j.coviro.2018.01.011_bib0450 article-title: High levels of hepatitis B surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis B viral loads publication-title: Ann Surg Oncol doi: 10.1245/s10434-014-4043-5 – volume: 143 year: 2012 ident: 10.1016/j.coviro.2018.01.011_bib0495 article-title: Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir publication-title: Gastroenterlogy doi: 10.1053/j.gastro.2012.05.039 – year: 2015 ident: 10.1016/j.coviro.2018.01.011_bib0375 article-title: Mechanisms downstream of reverse transcription reduce serum levels of HBV DNA but not of HBsAg in chronic hepatitis B virus infection publication-title: Virology J doi: 10.1186/s12985-015-0447-5 – year: 2015 ident: 10.1016/j.coviro.2018.01.011_bib0485 article-title: CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X publication-title: Scientific Rep doi: 10.1038/srep13734 – volume: 89 start-page: 1937 year: 2017 ident: 10.1016/j.coviro.2018.01.011_bib0380 article-title: Smaller reduction of hepatitis B virus DNA in liver tissue than in serum in patients losing HBeAg publication-title: J Med Virol doi: 10.1002/jmv.24841 |
| SSID | ssj0000561951 |
| Score | 2.2839282 |
| SecondaryResourceType | review_article |
| Snippet | •Loss of hepatitis B surface antigen (HBsAg) from blood is a criterion for cure.•Current antiviral treatment controls replication but rarely achieves HBsAg... A hallmark of hepatitis B virus (HBV) infection is the presence of hepatitis B surface antigen (HBsAg) in the serum of patients. Sustained loss of HBV DNA and... |
| SourceID | swepub proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 24 |
| SubjectTerms | 4-year entecavir therapy analog therapy Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Drug Discovery - trends Genetic Therapy - methods hbeag-negative hbsag seroclearance hbv integration Hepatitis B - drug therapy Hepatitis B - virology Hepatitis B virus - drug effects Hepatitis B virus - physiology hepatocellular-carcinoma Humans Infectious Medicine Infektionsmedicin linear dna liver-disease patients tenofovir disoproxil fumarate Virology virus dna Virus Integration - drug effects |
| Title | Impact of integrated viral DNA on the goal to clear hepatitis B surface antigen with different therapeutic strategies |
| URI | https://dx.doi.org/10.1016/j.coviro.2018.01.011 https://www.ncbi.nlm.nih.gov/pubmed/29453099 https://www.proquest.com/docview/2003051710 https://gup.ub.gu.se/publication/269040 |
| Volume | 30 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6SDYVeStPntk2YQunNXcuWZfm4TRM2Ld1LG8hN-CFttwR7ie1DL_ntmfGLPiiBgDFY1oDQSPOQZr4BeEdSUaQi056yrvBk4Esvc4nzSD1kpMD9TOd8oP91rVYX8vNldLkHJ2MuDIdVDrK_l-mdtB5aFsNsLnbb7eIb18km652vkVnxy304CEjb6xkcLM-_rNbTUQsbyUlXiJFJPKYZk-i6SK-84pQyDvPSHYSnEP9TUv8aoX8hjHZa6ewxPBrMSVz2Iz6EPVs-gQd9gclfT6E975IgsXI44UIUyHG9V_hpvcSqRDIAcVPRd1NhzjUk8IflKOtmW-NHrNtrl-YWaf4ZthP52BbHoioN_pa9hXUzok48g4uz0-8nK28otODltIUbekdRFsTa6SgJCherOHO51iqW1o8DlcbKt9KXRSRclBVOqzAshCPHOnRSJ2RxPYdZWZX2JaATqRVhwZ1Dyc4cuZcuCpxMyU_SuZpDOM6syQcUci6GcWXGcLOfpueHYX4YX9Aj5uBNVLseheOO_vHINPPHajKkKO6gfDvy2NBG49uTtLRVW3O9zpABzYQ_hxc986exBImMQrK15_C-Xw3TH0bv3rQ7Q02b1tTWBCohufnq3gN8DQ_5q49WewOz5rq1R2QXNdkx7H-4EcfD6r8FJsUL7w |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7SDaW9lL67fU6h9GbWsmVZPm7Tht0m2UsTyE34IW22BHuJ7UP_fWf8og9KoGAMliwQGmlmJM18H8AH0ooiFZn2lHWFJwNfeplLnEfmISMD7mc65wP9s41aXcivl9HlARyNuTAcVjno_l6nd9p6KFkMo7nY73aLb8yTTd47XyOz4Zd34FAyqfUMDpfrk9VmOmphJznpiBi5icdtxiS6LtIrrziljMO8dAfhKcS_jNTfTugfCKOdVTp-CA8GdxKXfY8fwYEtH8PdnmDyxxNo110SJFYOJ1yIAjmu9xo_b5ZYlUgOIG4r-m4qzJlDAq8sR1k3uxo_Yd3euDS3SOPPsJ3Ix7Y4kqo0-Ev2FtbNiDrxFC6Ov5wfrbyBaMHLaQk39I6iLIi101ESFC5WceZyrVUsrR8HKo2Vb6Uvi0i4KCucVmFYCEcb69BJnZDH9QxmZVXaF4BOpFaEBf8cSt7M0fbSRYGTKe2TdK7mEI4ja_IBhZzJMK7NGG723fTyMCwP4wt6xBy8qdW-R-G45f94FJr5bTYZMhS3tHw_ytjQQuPbk7S0VVszX2fIgGbCn8PzXvhTX4JERiH52nP42M-GqYbRu7ft3lDRtjW1NYFKSG--_O8OvoN7q_OzU3O63py8gvtc00euvYZZc9PaN-QjNdnbYQ38BHTPDdU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+integrated+viral+DNA+on+the+goal+to+clear+hepatitis+B+surface+antigen+with+different+therapeutic+strategies&rft.jtitle=Current+opinion+in+virology&rft.au=Lindh%2C+Magnus&rft.au=Rydell%2C+Gustaf+E&rft.au=Larsson%2C+Simon+B.&rft.date=2018-06-01&rft.issn=1879-6257&rft.volume=30&rft.spage=24&rft_id=info:doi/10.1016%2Fj.coviro.2018.01.011&rft.externalDocID=oai_gup_ub_gu_se_269040 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1879-6257&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1879-6257&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1879-6257&client=summon |